Toby A. Eyre
Churchill Drive
Oxford, ENG, United Kingdom
Oxford, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 192 publications
Erratum: High-Dose Methotrexate as CNS Prophylaxis in Ultra High-Risk Large B-Cell Lymphoma: An International Multicenter Analysis.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 27, 2026
An unanchored matching-adjusted indirect comparison of the efficacy of zanubrutinib versus ibrutinib for the treatment of relapsed/refractory mantle-cell lymphoma.
Journal: Journal of medical economics
Published: July 15, 2026
Erratum: Phase I/II Study of Sonrotoclax (BGB-11417) Monotherapy in Patients With Mantle Cell Lymphoma Previously Treated With Anti-CD20 Therapy and a Bruton Tyrosine Kinase Inhibitor.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 14, 2026
Phase I/II Study of Sonrotoclax (BGB-11417) Monotherapy in Patients With Mantle Cell Lymphoma Previously Treated With Anti-CD20 Therapy and a Bruton Tyrosine Kinase Inhibitor.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 01, 2026
High-Dose Methotrexate as CNS Prophylaxis in Ultra High-Risk Large B-Cell Lymphoma: An International Multicenter Analysis.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 11, 2026
Where next for BTKi-BCL2i combinations in mantle cell lymphoma?
Journal: British journal of haematology
Published: June 01, 2026
Modern Management of Mantle Cell Lymphoma.
Journal: American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting
Published: May 07, 2026
Fixed-duration pirtobrutinib plus venetoclax-rituximab versus venetoclax-rituximab for patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (BRUIN CLL-322): an open-label, multicentre, randomised, controlled, phase 3 trial.
Journal: Lancet (London, England)
Published: May 06, 2026
Cellular therapy in mantle cell lymphoma: recommendations from the EBMT practice harmonisation and guidelines committee.
Journal: Bone marrow transplantation
Published: March 08, 2026
Coronavirus disease 2019 (COVID-19) risk and evolving treatment patterns in follicular lymphoma during the pandemic: Insights from the PETReA trial.
Journal: British journal of haematology
Published: February 18, 2026
Last Updated: 09/26/2026